Subsection D – Exceptions to reasonable instructions for use § 201.100 – Medicinal products for human use subject to medical prescription. § 201.105 – Veterinary drugs. § 201.115 – New drugs or veterinary drugs. § 201.116 – Drugs for which directions for use are generally known. § 201.117 – Inactive ingredients. § 201.119 – In vitro diagnostic medical devices. § 201.120 – Prescription chemicals and other prescription ingredients. § 201.122 – Drugs for processing, repackaging or manufacture. § 201.125 – Drugs for teaching, law enforcement, research and analysis. § 201.127 – Drugs; Exceptions expire. § 201.128 – Meaning of the term “uses”.
§ 201.129 – Drugs; Tax exemption for radiopharmaceuticals for research purposes. 7) LABELLING AND ORDERING OF MEDICINES. (a) The establishment may not store prescription drugs for self-administration, self-administration or administration unless they are properly labelled and dispensed in accordance with Chapters 465 and 499, F.S., and Rule 64B16-28.108, F.C.A. When a personalized medication package is prepared for a resident and divided into individual medication containers, the following information must be noted on each individual container: 1. Name of resident; and 2. Identification of each drug in the container. (b) Except with respect to the use of pill organizers referred to in subsection (2), no person other than a pharmacist shall transfer drugs from one storage container to another. (c) If the directions for use are “as required” or “as prescribed”, contact the health care provider and ask for revised instructions. In the case of an “as needed” prescription, the circumstances in which it would be appropriate for the resident to request the drug and any restrictions must be indicated; For example: “as with pain, no more than 4 tablets per day.” Revised instructions, including the date they were received from the health care provider and the signatures of the staff who received them, should be noted in the medication record, or a revised label should be obtained from the pharmacist. (d) Any change to the instructions for use of a drug for which the facility provides assistance with self-administration or administration of medication must be accompanied by a written prescription issued and signed by the resident`s health care provider, or a prescription signed by fax or electronic copy of that prescription. New instructions should be immediately included in the resident`s medication monitoring protocol.
The establishment may then affix an “alarm label” to the drug container, instructing staff to review the revised instructions for use in the medication monitoring protocol or to obtain a revised label from the pharmacist. e) A nurse can take an order for medication over the phone. Such a prescription must be documented immediately in the resident`s medication monitoring protocol. The facility must receive a written medication instruction from the health care provider within 10 business days. A fax copy or an electronic copy of a signed order will be accepted. f) The facility must make every reasonable effort to ensure that prescriptions for residents who receive assistance with self-administration or medication are filled or renewed in a timely manner. (g) In accordance with subsection 465.0276(5), S.F., and Rule 61N-1.006, F.C.A., free prescription samples or drugs dispensed by a health care provider must be retained in the manufacturer`s original packaging, which must include the name of the physician, the name of the resident for whom they were dispensed and the date of delivery. If the sample or complementary medicinal products subject to medical prescription are not listed on the manufacturer`s label, they must be stored in a container with a label containing: 1. the name of the doctor; 2.
Name of resident; 3. Date of issue; 4. Name and dosage of the drug; 5. Instructions for use; and 6. Expiration date. (h) Pursuant to paragraph 465.0276(2)(c), F.O.A., the resident`s health care provider must provide the resident with a written prescription, fax or electronic copy of this prescription prior to the delivery of a sample or a free prescription drug. Subsection F – Drug labelling claims in drug efficacy studies § 201.200 – Disclosure of evaluations of drug efficacy studies in labelling and advertising. Subsection G – Special labelling requirements for certain medicinal products § 201.300 – Notice to manufacturers, packers and distributors of glandular preparations. § 201.301 – Notice to manufacturers, packers and distributors of estrogenic hormonal preparations.
§ 201.302 – Notice to manufacturers, packers and distributors of drugs for internal use containing mineral oil. § 201.303 – Labelling of medicinal preparations containing significant quantities of wintergreen oil. § 201.304 – Tannic acid and barium enema preparations. § 201.305 – Preparations for inhalation of isoproterenol (pressurized aerosols, nebulizers, powders) intended for human consumption; Warnings.